 - Orthos new VITROS Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measu re antibody response to SARS-CoV-2 - Ortho is the only company that offers laboratories in the U.S. a quantitative IgG test to the spike protein in addition to a total antibody test to the nucleocapsid protein RARITAN, N.J., July 9, 2021 PRNewswire -- Ortho Clinical Diagnostics Nasdaq: OCDX, one of the worlds largest pure-play in vitro diagnostics companies, today announced its VITROS Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration FDA Emergency Use Authorization EUA. 